PC
ANIK icon

Passport Capital’s Anika Therapeutics ANIK Stock Holding History

Passport Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,047
Closed -$414K – 209
2015
Q1 		$414K Buy
+10,047
New +$406K 0.01% 145

Other funds holding ANIK

TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LCP
Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Passport Capital's ANIK Position: Q2 2015 in Review

Passport Capital sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 10,047 shares — an estimated $414K sold.

Passport Capital first reported a position in ANIK in Q1 2015 and held it in 1 quarter. The position peaked at $414K in Q1 2015. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

  • Passport Capital reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Passport Capital sold 10,047 Anika Therapeutics shares in Q2 2015, an estimated $414K.
  • Passport Capital first reported a position in Anika Therapeutics in Q1 2015 and held it in 1 quarter.
  • Passport Capital's Anika Therapeutics position peaked at $414K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on Passport Capital's 13F filing for Q2 2015, filed 14 Aug 2015.